Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall D1
Objectives: To evaluate the influence of single nucleotide polymorphisms (SNP)of IL10, TNFα, IFNγand IL18 in the incidence of CMV infection in renal transplant recipients. Methods: A retrospective cohort study from a prospective database included 709 patients that received a renal transplant at our center between 2005-2013. We excluded re-transplant, not Caucasian, primary graft failure or death in the early post-transplant. SNP analysis was performed by real-time PCR with Taqman® probes. The patients were stratified according to the higher producing genotype. Results: The incidence of CMV infection and disease was of 37% and 6.4% respectively.The main risk factors are described in tables 1 and 2. There was a significant independent association between SNP -137 G/C of IL18 and CMV infection, where carriers of G allele had a higher risk of CMV infection (OR=2.79; CI 95%: 1.00-7.78; p=0.044). In the subgroup of patients that received prophylaxis for CMV, the main risk factor for infection after discontinuation of Valgancyclovir was being a carrier of G allele (OR=5.10; CI 95%: 1.12-23.20; p=0.035). No patients developed CMV disease within non-carriers.
|CMV INFECTION (REGRESSION MODEL)||OR (CI 95%)||P|
|GG/GC VS CC||2.79 (1.01-7.78)||0.044|
|ACUTE VASCULAR REJECTION|
|YES VS NO||2.63 (1.55-4.45)||<0.01|
|>60 YEARS VS <60 YEARS||1.73 (1.11-2.69)||0.014|
|COLD ISCHEMIA TIME|
|>18H VS < 18H||1.64 (1.07-2.50)||0.022|
|DELAYED GRAFT FUNCTION|
|YES VS NO||1.63 (1.06-2.51)||0.026|
|CMV DISEASE||OR (CI 95%)||P|
|ACUTE VASCULAR REJECTION(YES VS NO)||6.83(3.01-15.59)||<0.01|
|CMVIgG (D+/R-) VS (D-/R+ & D+/R+)||3.74(1.54-9.08)||0.003|
Conclusions: SNP -137G/C of IL18 can affect the incidence of CMV infection and response towards prophylaxis with Valgancyclovir. The knowledge of these polymorphisms in recipients previous to transplantation and a closer virologicalmonitorization in those patients with a higher risk of CMV infection can aid in the individualization of treatment regimens and lower the rate of infectious complications.
CITATION INFORMATION: Perez-Flores I, Moreno De La Higuera M, Calvo Romero N, Rodriguez Cubillo B, Shabaka A, Calvo Arevalo M, Lopez De La Manzanara V, Sanchez-Fructuoso A. CMV Infection in Renal Transplant Recipients: Incidence and Efficacy of Prophylaxis According to Cytokine Single Nucleotide Polymorphisms. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Perez-Flores I, Moreno M, Calvo N, Rodriguez B, Shabaka A, Calvo M, Lopez V, Sanchez-Fructuoso A. CMV Infection in Renal Transplant Recipients: Incidence and Efficacy of Prophylaxis According to Cytokine Single Nucleotide Polymorphisms. [abstract]. Am J Transplant. 2017; 17 (suppl 3). http://atcmeetingabstracts.com/abstract/cmv-infection-in-renal-transplant-recipients-incidence-and-efficacy-of-prophylaxis-according-to-cytokine-single-nucleotide-polymorphisms/. Accessed February 22, 2018.
« Back to 2017 American Transplant Congress